Literature DB >> 26361713

Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys.

Kathryn L Schwienteck1, Matthew L Banks2.   

Abstract

BACKGROUND: Methamphetamine addiction is a significant public health problem for which no Food and Drug Administration-approved pharmacotherapies exist. Preclinical drug vs. food choice procedures have been predictive of clinical medication efficacy in the treatment of opioid and cocaine addiction. Whether preclinical choice procedures are predictive of candidate medication effects for other abused drugs, such as methamphetamine, remains unclear. The present study aim was to determine continuous 7-day treatment effects with the monoamine releaser d-amphetamine and the monoamine uptake inhibitor methylphenidate on methamphetamine vs. food choice. In addition, 7-day cocaine treatment effects were also examined.
METHODS: Behavior was maintained under a concurrent schedule of food delivery (1-g pellets, fixed-ratio 100 schedule) and methamphetamine injections (0-0.32mg/kg/injection, fixed-ratio 10 schedule) in male rhesus monkeys (n=4). Methamphetamine choice dose-effect functions were determined daily before and during 7-day periods of continuous intravenous treatment with d-amphetamine (0.01-0.1mg/kg/h), methylphenidate (0.032-0.32mg/kg/h), or cocaine (0.1-0.32mg/kg/h).
RESULTS: During saline treatment, increasing methamphetamine doses resulted in a corresponding increase in methamphetamine vs. food choice. Continuous 7-day treatments with d-amphetamine, methylphenidate or cocaine did not significantly attenuate methamphetamine vs. food choice up to doses that decreased rates of operant responding. However, 0.1mg/kg/h d-amphetamine did eliminate methamphetamine choice in two monkeys.
CONCLUSIONS: The present subchronic treatment results support the utility of preclinical methamphetamine choice to evaluate candidate medications for methamphetamine addiction. Furthermore, these results confirm and extend previous results demonstrating differential pharmacological mechanisms between cocaine choice and methamphetamine choice.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Amphetamine; Choice; Cocaine; Methamphetamine; Methylphenidate

Mesh:

Substances:

Year:  2015        PMID: 26361713      PMCID: PMC4582002          DOI: 10.1016/j.drugalcdep.2015.08.022

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  39 in total

1.  Narcotic blockade.

Authors:  V P Dole; M E Nyswander; M J Kreek
Journal:  Arch Intern Med       Date:  1966-10

2.  Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin.

Authors:  R R Griffiths; R M Wurster; J V Brady
Journal:  Pharmacol Rev       Date:  1975-09       Impact factor: 25.468

3.  Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.

Authors:  S Wayne Miles; Janie Sheridan; Bruce Russell; Rob Kydd; Amanda Wheeler; Carina Walters; Greg Gamble; Peta Hardley; Maree Jensen; Kimmo Kuoppasalmi; Pekka Tuomola; Jaana Föhr; Outi Kuikanmäki; Helena Vorma; Raimo Salokangas; Antti Mikkonen; Mika Kallio; Jussi Kauhanen; Vesa Kiviniemi; Jari Tiihonen
Journal:  Addiction       Date:  2013-03-01       Impact factor: 6.526

4.  Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation.

Authors:  R White
Journal:  Addiction       Date:  2000-02       Impact factor: 6.526

5.  Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys.

Authors:  William S John; Amy Hauck Newman; Michael A Nader
Journal:  Neuropharmacology       Date:  2015-01-06       Impact factor: 5.250

Review 6.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

Review 7.  Medications development for opioid abuse.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

8.  Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.

Authors:  Walter Ling; Linda Chang; Maureen Hillhouse; Alfonso Ang; Joan Striebel; Jessica Jenkins; Jasmin Hernandez; Mary Olaer; Larissa Mooney; Susan Reed; Erin Fukaya; Shannon Kogachi; Daniel Alicata; Nataliya Holmes; Asher Esagoff
Journal:  Addiction       Date:  2014-07-08       Impact factor: 6.526

9.  Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.

Authors:  Maija Konstenius; Nitya Jayaram-Lindström; Joar Guterstam; Olof Beck; Björn Philips; Johan Franck
Journal:  Addiction       Date:  2013-12-01       Impact factor: 6.526

10.  Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Adv Pharmacol Sci       Date:  2012-11-28
View more
  8 in total

1.  Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Authors:  Amy R Johnson; Matthew L Banks; Dana E Selley; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2018-04-19       Impact factor: 7.853

2.  An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men.

Authors:  Matthew J Mimiaga; David W Pantalone; Katie B Biello; Jackie M White Hughto; John Frank; Conall O'Cleirigh; Sari L Reisner; Arjee Restar; Kenneth H Mayer; Steven A Safren
Journal:  AIDS Care       Date:  2019-03-19

Review 3.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

4.  Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.

Authors:  Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2016-05-27       Impact factor: 4.492

Review 5.  Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.

Authors:  Matthew L Banks
Journal:  Ann N Y Acad Sci       Date:  2016-12-09       Impact factor: 5.691

Review 6.  Insights from Preclinical Choice Models on Treating Drug Addiction.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Trends Pharmacol Sci       Date:  2016-12-02       Impact factor: 14.819

7.  Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys.

Authors:  Matthew L Banks; Douglas A Smith; Bruce E Blough
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

8.  Neuroimaging Metrics of Drug and Food Processing in Cocaine-Dependence, as a Function of Psychopathic Traits and Substance Use Severity.

Authors:  William J Denomme; Isabelle Simard; Matthew S Shane
Journal:  Front Hum Neurosci       Date:  2018-09-04       Impact factor: 3.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.